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1. introduction 
Fusidic acid stimulates the in vivo incorporation 
of amino acids into proteins of rat liver, kidney, brain 
and muscle [ 1 ] . The mode of action for this stimula- 
tion is as yet unclear. Modification of protein struc- 
ture is known to play an important role in cellular 
metabolism. Phosphorylation of proteins, one of the 
important modifications of protein structure [2], 
is induced by hormones (glucagon) and effecters 
(CAMP) in rat liver [3,4]. Only one of the ribosomal 
proteins of rat liver, S6, is phosphorylated in vivo [5]. 
This phosphorylation can also be stimulated by 
glucagon and CAMP [6,7], during liver regeneration 
[5] and by the protein synthesis inhibitors, cyclo- 
heximide and puromycin [8]. 
We have observed that fusidic acid enhances the 
uptake of 32P into the liver intracellular phosphate 
pool and stimulates the in vivo phosphorylation of 
proteins in all of the cell fractions of the rat liver 
except mitochondria. This increase in phosphoryla- 
tion is positively correiated with the previously report- 
ed [ 1 ] in vivo stimulation of protein synthesis. How- 
ever, when cycloheximide, an inhibitor of protein 
synthesis, is administered prior to fusidic acid, the 
phosphorylation effects of the two compounds are 
additive while protein synthesis is inhibited. Although 
fusidic acid elevates blood glucose it does not signifi- 
cantly enhance mitochondrial protein phosphorylation 
as does glucagon [3] . 
2. Materials and methods 
Female (170-190 g) and male (200-220 g) fed 
Sprague-Dawley strain rats were injected i.p. with 
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cycloheximide (5 mg/lOO g b.w.) in 1 ml of 0.9% 
saline; control animals received the identical volume 
of saline alone. Thirty minutes later, a mixture con- 
taining 22 &i of L[4,5-3H]leucine (Amersham-Searle, 
46 Ci/mmol), 670 I.tCi carrier-free [““PI orthophos- 
phoric acid in 0.02 N HCl (New England Nuclear, 
15 mCi/ 182 ~1) and 10 mg sodium fusidate (a gift 
from Dr W. 0. Godtfredsen, Leo Pharmaceutical 
Products, Ballerup, Denmark) dissolved in 0.9% saline 
to a total volume of one ml was administered to the 
rats. Control rats received the same mixture without 
sodium fusidate. Twenty minutes after receiving the 
isotopes, the rats were decapitated, livers removed 
and homogenized in 3 volumes of 0.25 M sucrose- 
TKM (50 mM Tris-HCl, 25 mM KCl, 10 mM MgC12, 
pH 7.5). Mitochondria were prepared according to 
Sottocasa et al. [9]. Endoplasmic reticulum, poly 
ribosomes and post-microsomal supernatant were 
prepared according to Sunshine et al. [lo] , except 
that the MgC12 concentration of the 0.25 M sucrose- 
TKM was increased from 5 to 10 mM [l l] . Ribosomal 
subunits (a mixture of 40s and 60s) were prepared 
according to Gressner and Wool [5]. Determination 
of radioactivity in protein was by the method of 
Mans and Novelli [ 121; protein was determined 
according to Lowry et al. [ 131. Plasma and liver 
homogenate concentration of Pi were assayed by 
the method of Fiske and Subbarow [14]. Data present- 
ed in this paper are from results obtained using female 
rats, as no significant difference was observed between 
sexes. 
3. Results and discussion 
Phosphorylation of proteins isolated from all liver 
cell fractions except mitochondria were significantly 
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Table 1 
September 1976 
The influence of fusidic acid and cycloheximide on the incorporation of [“PI orthophosphate and 
[ ‘Hlleucine into rat liver organelle proteins 
cpm/mg protein 
Treatment No of 
rats 
Isotope Homogenate Mitoa RERa SERa PMSa Ribosomes 
Ribo- 
somal 
subunits 
Control 3 s*P 1410 3760 8570 3370 1350 5640 1500 
sH 9910 22 720 16540 15 810 5000 11970 4660 
Fusidic acid 3 s2P 2450 4030 12 050 5470 1780 8460 3450 
sH 18 780 26960 24720 26900 7540 16 430 6540 
Cycloheximide 2 =P 1730 3000 10 080 2780 1590 7670 3000 
jH 310 570 1840 2010 250 2010 1020 
Cycloheximide 
plus fusidic acid 2 s2P 3430 4760 15 710 5900 2140 11790 5270 
3H 500 910 2410 3030 215 3030 1230 
aMito, mitochondria; RER, rough endoplasmic reticulum; SER, smooth endoplasmic reticulum; PMS, postmicrosomal supernatant. 
increased (rough endoplasmic reticulum, 40%; smooth 
endoplasmic reticulum, 62%; polyribosomes, 50%; 
ribosomal subunits, 130%; post-microsomal super- 
natant, 32%) as was the incorporation of 3H from 
leucine into these proteins (including mitochondria) 
(19 to 89% increase) by sodium fusidate (table 1). 
This sodium fusidate-induced increase in specific 
activity of 32P in the proteins is much greater than that 
from cycloheximide, but less than those reported [3] 
for glucagon induction. However, if one compares 
specific activities at 20 min then only phosphoryla- 
tion of the mitochondrial fraction is stimulated to a 
greater extent by glucagon. Our data support those of 
Gressner and Wool [8] who were the first to show that 
cycloheximide stimulates phosphorylation of ribo- 
somes while inhibiting protein synthesis. When cyclo- 
heximide and sodium fusidate were administered 
sequentially, the phosphorylation effects tended to be 
additive in the majority of cell fraction proteins. How- 
ever, sodium fusidate failed to significantly alter the 
inhibition by cycloheximide of the incorporation of 
3H from leucine into protein. Thus, modification of 
protein structure by phosphorylation is not an absolute 
requirement for the inhibition or stimulation of in vivo 
protein synthesis. Fusidic acid appears to enhance the 
phosphorylation of existing proteins and not newly 
synthesized proteins since maximum phosphorylation 
occurs under limited protein synthesis (cycloheximide 
plus fusidic acid). Further purification of cleavage of 
ribosomes to subunits by puromycin increased the 
phosphorylation values due to sodium fusidate more 
than 2-fold. 
Sodium fusidate also increases the specific activity 
of the intracellular phosphate pool through facilitated 
Table 2 
The effect of fusidic acid on facilitated transport of Pi from plasma to liver in fed female rats 
rmol Pi/g 
Treatment liver 
Control 4.32 
Fusidic acid 4.89 
Cycloheximide 4.44 
Cycloheximide 
plus fusidic acid 4.98 
aRatio l/p; liver/plasma. 
pm01 Pi/ml 
plasma 
1.28 
1.27 
1.44 
1.56 
Ratioa cpm X 10w6/ Ratio 
IlP 
mol Pi 
Liver plasma l/p 
3.38 3.7 7.0 0.53 
3.93 4.8 4.8 1.00 
3.08 3.2 6.0 0.53 
3.19 5.1 5.5 0.93 
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uptake (13% increase, fusidic) of 32P into the liver 
(table 2). This is less than the stimulation action 
reported for glucagon [3,15,16]. Cycloheximide alone 
had no apparent effect on facilitated transport nor 
did it inhibit the transport elicited by sodium fusidate 
(15% increase, fusidic plus cycloheximide). Equilibra- 
tion of the 32P phosphate pool between liver and 
plasma is reached by 20 min under the influence of 
sodium fusidate alone or in the presence of cyclo- 
heximide. Sodium fusidate may stimulate the glucagon- 
dependent activation of the protein-phosphorylating 
process [ 171. Thus, increased intracellular phosphoryla- 
tion of liver proteins by fusidic acid may be mediated 
through CAMP-activated protein kinases since we have 
found a significant increase in blood glucose (1.5-fold) 
and plasma CAMP (4-fold) but no change in liver CAMP 
at 20 minutes post-sodium fusidate (unpublished data 
of Ziv and Stratman). 
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